+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Encephalopathy - Pipeline Review, H1 2020

  • PDF Icon

    Drug Pipelines

  • 81 Pages
  • June 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5130283
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Pipeline Review, H1 2020, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.

Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Encephalopathy - Overview
  • Encephalopathy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Encephalopathy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Encephalopathy - Companies Involved in Therapeutics Development
  • BrainRepair UG
  • Celularity Inc
  • Gene Therapy Research Institution Co Ltd
  • GW Pharmaceuticals Plc
  • Hope Biosciences LLC
  • Inflazome Ltd
  • JS Genetics Inc
  • Mesoblast Ltd
  • Mithra Pharmaceuticals SA
  • Mononuclear Therapeutics Ltd
  • Orphan Star Therapeutics LLC
  • Pfizer Inc
  • ProThera Biologics Inc
  • ReAlta Life Sciences Inc
  • SL Bigen Inc
  • Worphmed Srl
  • Encephalopathy - Drug Profiles
  • Alda-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CL-2020 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • diazoxide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Target SLC2A1 for Glut1 Deficiency Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • estetrol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate SLC2A1 for GLUT1 Deficiency Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GT-0006X - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GWP-42003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MCC-950 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • melatonin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Inhibit IL-2 for Encephalopathy, Graft Versus Host Disease and Type 1 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PSC-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remestemcel-L - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RLS-0071 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SLBM-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Anemia and Hypoxic Ischemic Encephalopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Encephalopathy - Dormant Projects
  • Encephalopathy - Discontinued Products
  • Encephalopathy - Product Development Milestones
  • Featured News & Press Releases
  • Apr 02, 2019: Mithra receives orphan drug designation from FDA for E4 in neonatal encephalopathy treatment
  • Apr 02, 2019: Mithra receives orphan drug designation from FDA for E4 in neonatal encephalopathy treatment
  • Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy
  • Mar 17, 2017: Sanofi awarded new funding to Monani Lab to study glucose transporter-1 deficiency syndrome
  • Dec 31, 2016: Defining the Spatial and Temporal Requirements for the Glucose Transporter-1 protein in Glut1 Deficiency Syndrome
  • Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
  • Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer

List of Tables
  • Number of Products under Development for Encephalopathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Encephalopathy - Pipeline by BrainRepair UG, H1 2020
  • Encephalopathy - Pipeline by Celularity Inc, H1 2020
  • Encephalopathy - Pipeline by Gene Therapy Research Institution Co Ltd, H1 2020
  • Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H1 2020
  • Encephalopathy - Pipeline by Hope Biosciences LLC, H1 2020
  • Encephalopathy - Pipeline by Inflazome Ltd, H1 2020
  • Encephalopathy - Pipeline by JS Genetics Inc, H1 2020
  • Encephalopathy - Pipeline by Mesoblast Ltd, H1 2020
  • Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, H1 2020
  • Encephalopathy - Pipeline by Mononuclear Therapeutics Ltd, H1 2020
  • Encephalopathy - Pipeline by Orphan Star Therapeutics LLC, H1 2020
  • Encephalopathy - Pipeline by Pfizer Inc, H1 2020
  • Encephalopathy - Pipeline by ProThera Biologics Inc, H1 2020
  • Encephalopathy - Pipeline by ReAlta Life Sciences Inc, H1 2020
  • Encephalopathy - Pipeline by SL Bigen Inc, H1 2020
  • Encephalopathy - Pipeline by Worphmed Srl, H1 2020
  • Encephalopathy - Dormant Projects, H1 2020
  • Encephalopathy - Discontinued Products, H1 2020

List of Figures
  • Number of Products under Development for Encephalopathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • BrainRepair UG
  • Celularity Inc
  • Gene Therapy Research Institution Co Ltd
  • GW Pharmaceuticals Plc
  • Hope Biosciences LLC
  • Inflazome Ltd
  • JS Genetics Inc
  • Mesoblast Ltd
  • Mithra Pharmaceuticals SA
  • Mononuclear Therapeutics Ltd
  • Orphan Star Therapeutics LLC
  • Pfizer Inc
  • ProThera Biologics Inc
  • ReAlta Life Sciences Inc
  • SL Bigen Inc
  • Worphmed Srl